They did. Particular countries that are following and actually recording these kinds of shortages, such as Germany and France, experienced a 60% increase in shortages over the first few months of the pandemic. In fact, our group at the University of Toronto found about three different kinds of responses among high-income countries.
In Europe, they have enough capacity that they were able to make critical drugs domestically. The U.S. did something similar but they actually activated their Defense Production Act. It mandated that everything had to be made in the U.S., and they would not really take over factories but be able to use their capacity in factories. That's what they've done for their vaccines as well.
We're challenged in Canada because we really only have one plant that could make injectables. It's an older plant that doesn't make all the injectables. We're also challenged in that the choke point in the global supply chain is that 70% of the precursors come from China. India probably makes about 20% to 30%. We have more diversity when it comes to the actual drugs, but the precursors themselves have been quite a challenge for a lot of people.